Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | CD40 | P25942 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243908 | 0.95 | OPRD1 (0.55) | OPRD1OPRM1OPRK1CD40OPRL1 | |
| SCHEMBL11592659 | 0.94 | OPRD1 (0.60) | OPRD1OPRM1OPRK1ERAP2LNPEP | |
| SCHEMBL11512382 | 0.93 | IL23R (0.51) | OPRD1OPRM1OPRK1CD40 | |
| SCHEMBL31243865 | 0.93 | OPRD1 (0.58) | OPRD1OPRM1OPRK1CD40OPRL1 | |
| SCHEMBL31243859 | 0.93 | OPRD1 (0.58) | OPRD1OPRM1OPRK1CD40OPRL1 | |
| SCHEMBL31243884 | 0.91 | OPRD1 (0.57) | OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL31243878 | 0.91 | OPRD1 (0.59) | OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL31243945 | 0.91 | OPRD1 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31243858 | 0.90 | TFPI (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31243925 | 0.90 | TFPI (0.60) | OPRD1OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | OPRD1 4807/4885OPRM1 4813/4885OPRK1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.